Global Anti-Obesity Drugs Market Report 2026: Set To Reach $106.5 Billion By 2035 As GLP-1 Therapies Transform Obesity Care
Dublin, Sept. 01, 2026 (GLOBE NEWSWIRE) -- The "Anti-Obesity Drugs Market by Type of Molecule, Type of Drug, Active Compound, Mechanism of Action, Type of Agonist, Action Pathway, Route of Administration, Distribution Channel, Geographical Regions, and Key Players - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering.
The global anti-obesity drugs market is projected to grow from USD 45.1 billion in 2026 to USD 106.5 billion by 2035, representing a compound annual growth rate of approximately 10.0% during the forecast period. Rising obesity prevalence, expanding clinical evidence, next-generation drug development and increasing access to prescription weight-loss therapies are expected to support sustained market expansion.
Anti-Obesity Drugs Market Growth and Trends
Obesity remains a major global public health challenge. Data compiled by the NCD Risk Factor Collaboration indicates that more than one billion people worldwide are living with obesity, including approximately 880 million adults and 159 million children and adolescents. The association between obesity and diabetes, cardiovascular disease, renal complications and several cancers is intensifying demand for effective pharmacological treatments.
GLP-1 receptor agonists have become a defining force in the anti-obesity drugs market. Therapies containing semaglutide and tirzepatide have delivered significant weight-loss outcomes, accelerating physician adoption and increasing investment across the pharmaceutical industry. Clinical findings are also broadening the role of these treatments beyond weight management. The SELECT cardiovascular outcomes trial, for example, found that semaglutide reduced the risk of major adverse cardiovascular events by 20% in overweight or obese adults with established cardiovascular disease.
The transition from injectable treatments to oral anti-obesity drugs represents another important market opportunity. Oral therapies may reduce cold-chain requirements, distribution costs and barriers related to injectable administration. OPKO Health and Entera Bio are jointly developing OPK-88006, an oral, once-daily dual GLP-1/glucagon agonist. Other oral candidates, including orforglipron and ECC5004, could further improve treatment access following regulatory approval.
Key Anti-Obesity Drugs Market Growth Drivers
- Rising obesity prevalence: Increasing adult and pediatric obesity rates are placing pressure on governments, healthcare providers and payers to expand access to clinically validated treatments. Benefits beyond weight reduction: GLP-1 and multi-agonist therapies have demonstrated cardiovascular, renal, glycemic and metabolic benefits, supporting broader indications and potentially longer treatment durations. Expanding clinical pipeline: Late-stage candidates such as CagriSema, retatrutide and survodutide are diversifying the market beyond established single-agonist therapies. Strategic investment and expansion: Pharmaceutical and digital-health companies are pursuing manufacturing investments, partnerships and acquisitions to strengthen their positions in high-growth obesity markets.
Market Challenges
High research and development costs remain a significant barrier for anti-obesity drug developers. Long-term clinical studies are required to demonstrate durable weight loss, cardiometabolic benefits and acceptable safety profiles. Stringent regulatory review can further increase development timelines and commercialization costs.
Manufacturing capacity is another major constraint. Novo Nordisk and Eli Lilly have experienced supply pressure as demand for GLP-1 therapies has exceeded available production capacity. Market adoption may also be affected by adverse events, long-term safety considerations and patient perceptions. Continued post-marketing surveillance, transparent clinical communication and physician education will remain essential.
Competitive Landscape and Emerging Opportunities
Eli Lilly and Novo Nordisk currently lead the global anti-obesity drugs market, but competition is expanding. Roche has announced a USD 2 billion investment to increase US manufacturing capacity for obesity treatments, while Teva's introduction of generic liraglutide indicates growing competition across branded and generic products.
Mergers and acquisitions are also supporting geographic expansion. Voy's acquisition of India-based online weight-management platform EarlyFit illustrates how companies can gain faster entry into large, underpenetrated markets through established digital distribution networks.
Biologics account for the largest share of the development pipeline, with GLP-1-based products maintaining a prominent position. Nevertheless, oral therapies and small-molecule candidates could reshape the competitive landscape by improving convenience, scalability and access in cost-sensitive markets.
Key Market Segmentation Insights
- By molecule: Biologics lead the market, while small molecules represent an emerging opportunity. By drug type: Prescription anti-obesity drugs hold the largest share, supported by clinical validation and physician oversight. Over-the-counter products are expected to grow as demand for accessible weight-management options increases. By active compound: Tirzepatide accounts for more than 45% of the active-compound segment. Semaglutide, retatrutide, survodutide, CagriSema, orforglipron and liraglutide are also included in the market assessment. By mechanism of action: GLP-1 agonists remain dominant, while dual GLP-1/GCGR agonists are projected to record strong growth. The market also includes GLP-1/GIP, GLP-1/amylin and triple-agonist mechanisms. By administration route: Parenteral therapies currently set the clinical benchmark, while oral anti-obesity drugs are expected to gain momentum. By distribution channel: The market includes hospital pharmacies and retail and online pharmacies.
Regional Anti-Obesity Drugs Market Outlook
North America currently generates the largest share of global anti-obesity drug revenue, supported by high obesity prevalence, established healthcare infrastructure and comparatively favorable reimbursement pathways. The United States remains a major center for clinical development, commercialization and manufacturing investment.
Asia-Pacific is projected to register the fastest regional growth through 2035. Rising obesity rates, urbanization, greater healthcare spending and expanding treatment access in China, India, Japan, South Korea and Australia are creating substantial opportunities. The report also assesses Europe and Latin America, including Germany, the UK, France, Italy, Spain, Brazil and Argentina.
Leading Companies in the Anti-Obesity Drugs Market
- Eli Lilly Novo Nordisk Pfizer AstraZeneca Roche Boehringer Ingelheim Zealand Pharma Viking Therapeutics Regeneron
Research Coverage
The report provides anti-obesity drugs market sizing and opportunity analysis by molecule type, drug type, active compound, mechanism of action, agonist type, action pathway, route of administration, distribution channel and geography. It also evaluates the competitive landscape, company pipelines, strategic initiatives, manufacturing expansion, partnerships, acquisitions and the market impact of major drivers, restraints, opportunities and challenges.
The research incorporates perspectives from executives, endocrinologists, medical researchers, academic specialists and pharmaceutical industry leaders in the United States, Canada and Denmark. It addresses the current and projected market size, leading segments, fastest-growing regions, competitive positioning and the expected impact of oral anti-obesity therapies.
Report Benefits
- Comprehensive revenue forecasts and segment-level market analysis Competitive intelligence covering established companies and emerging entrants Assessment of oral therapies, biologics, small molecules and multi-agonist candidates Regional opportunity analysis for North America, Europe, Asia-Pacific and Latin America Insights to support product development, pricing, market-entry and partnership strategies PowerPoint insights pack and Excel data packs for analytical modules Up to 15% complimentary content customization Research team walkthrough and a complimentary update for qualifying reports
With obesity prevalence continuing to rise and clinical innovation accelerating, the global anti-obesity drugs market is positioned for substantial growth through 2035. Expanding indications, oral drug development, manufacturing investment and competition among major pharmaceutical companies are expected to transform obesity treatment and create significant commercial opportunities worldwide.
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment